AK0406: New Long-Acting Influenza Antiviral Approved in China
Shanghai Ark Biopharmaceutical Co., Ltd announced today that China’s National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for AK0406 injection, the company’s first antiviral drug-Fc conjugate (AFC) candidate designed for long-acting influenza prevention. The approval makes AK0406 the first influenza-focused AFC candidate in China to progress into clinical development.
AK0406 is a next-generation, long-acting antiviral candidate discovered and developed by ArkBio. The molecule combines a highly potent antiviral small-molecule agent with an antibody Fc fragment through targeted conjugation, with the aim of delivering sustained protection before and after exposure and potentially offering therapeutic benefits.
This approach is intended to address the continuing need for effective influenza prevention, particularly during periods of high seasonal transmission. Preclinical studies indicate that AK0406 has potent and broad activity against both influenza A and influenza B viruses, while retaining immune effector activity and achieving prolonged systemic exposure. Its molecular design is intended to provide a balanced profile suitable for both influenza prophylaxis and treatment.
ArkBio is also advancing AK0406 through international clinical development. In February 2026, the company received authorization from an Australian Human Research Ethics Committee (HREC) to begin a Phase I study. Recruitment and dosing of healthy adult participants across all planned cohorts in Australia have been completed, and the study has subsequently moved into the follow-up stage.
Influenza continues to represent a substantial global public health burden. Existing prevention strategies rely heavily on seasonal vaccination, but these approaches have inherent challenges. These include the difficulty of accurately anticipating and matching circulating viral strains each year, the effects of ongoing antigenic drift, and lower levels of vaccine protection in certain vulnerable groups, including older adults and people with compromised immune systems. Consequently, significant unmet needs remain in influenza prevention.
ArkBio plans to work closely with China’s Center for Drug Evaluation (CDE) to support the continued clinical development of AK0406 in China while completing follow-up activities associated with the Phase I study in Australia. Through a coordinated development strategy spanning China and international markets, the company intends to advance the program efficiently and ultimately develop a safe, effective, and convenient option for influenza prevention worldwide.
AK0406 is a next-generation, long-acting antiviral candidate discovered and developed by ArkBio. The molecule combines a highly potent antiviral small-molecule agent with an antibody Fc fragment through targeted conjugation, with the aim of delivering sustained protection before and after exposure and potentially offering therapeutic benefits.
This approach is intended to address the continuing need for effective influenza prevention, particularly during periods of high seasonal transmission. Preclinical studies indicate that AK0406 has potent and broad activity against both influenza A and influenza B viruses, while retaining immune effector activity and achieving prolonged systemic exposure. Its molecular design is intended to provide a balanced profile suitable for both influenza prophylaxis and treatment.
ArkBio is also advancing AK0406 through international clinical development. In February 2026, the company received authorization from an Australian Human Research Ethics Committee (HREC) to begin a Phase I study. Recruitment and dosing of healthy adult participants across all planned cohorts in Australia have been completed, and the study has subsequently moved into the follow-up stage.
Influenza continues to represent a substantial global public health burden. Existing prevention strategies rely heavily on seasonal vaccination, but these approaches have inherent challenges. These include the difficulty of accurately anticipating and matching circulating viral strains each year, the effects of ongoing antigenic drift, and lower levels of vaccine protection in certain vulnerable groups, including older adults and people with compromised immune systems. Consequently, significant unmet needs remain in influenza prevention.
ArkBio plans to work closely with China’s Center for Drug Evaluation (CDE) to support the continued clinical development of AK0406 in China while completing follow-up activities associated with the Phase I study in Australia. Through a coordinated development strategy spanning China and international markets, the company intends to advance the program efficiently and ultimately develop a safe, effective, and convenient option for influenza prevention worldwide.
Companies